LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Sponsor: Beth Israel Deaconess Medical Center
A PHASE1/PHASE2 clinical study on Malignant Glioma, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Genentech, Inc.
- Massachusetts General Hospital
- Northwestern University
- Novartis
- Patrick Y. Wen, MD
- University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .